Ryan Asay | VP of Corporate Affairs |
David Meek | CEO |
Charles Baum | President, Founder and Head of R&D |
Laurie Stelzer | CFO |
James Christensen | Chief Scientific Officer |
Ben Hickey | Chief Commercial Officer |
Alan Sandler | Chief Medical Officer |
Tyler Van Buren | Cowen and Company |
Salveen Richter | Goldman Sachs |
Harshita Polishetty | Barclays |
Jonathan Miller | Evercore ISI |
Michael Schmidt | Guggenheim |
Neil Carnahan | Stifel |
Noah Burhance | JPMorgan |
Jason Gerberry | Bank of America |
Michael Ulz | Morgan Stanley |
Yigal Nochomovitz | Citigroup |
Maury Raycroft | Jefferies |
Evan Seigerman | BMO |
Ami Fadia | Needham |
Andrew Fleszar | B. Riley Securities |
Jay Olson | Oppenheimer |
Good afternoon and welcome to the Mirati Therapeutics Fourth Quarter 2022 Earnings Call. My name is Cynthia and I'll be the operator for today's call. [Operator Instructions]
It is my pleasure to introduce Ryan Asay, Vice President of Corporate Affairs at Mirati. Ryan, you may begin the call.